Precision Neuroscience Breakthroughs: Abe Ceesay, CEO of Rapport Therapeutics I Future of Biotech
Synopsis:
Abe Ceesay, CEO of Rapport Therapeutics, sits down with host Rahul Chaturvedi to reveal how precision neuroscience is driving revolutionary treatments for neurological disorders. They explore Rapport’s cutting-edge lead program targeting focal epilepsy and discuss the groundbreaking advancements that are reshaping the landscape of drug development. Abe also shares his dynamic leadership journey, offering insights into the biotech industry’s future and how innovative approaches are delivering life-changing treatments. Don’t miss this powerful discussion on the future of precision medicine and the hope it brings to patients with neurological conditions.
Biography:
Abe brings nearly two decades of biopharmaceutical industry experience to Rapport. He served as President of Cerevel Therapeutics from May 2021 through February 2023, and was previously CEO of Tiburio Therapeutics, where he built a fully integrated company that led to the investigational new drug enablement for a rare neuroendocrine tumor. Prior to joining Tiburio, Mr. Ceesay held positions including Chief Operating Officer at scPharmaceuticals, Head of Commercial at Keryx Biopharmaceuticals, Vice President of Marketing at Ironwood Pharmaceuticals, and roles of increasing responsibility at Sanofi, formerly Genzyme. Mr. Ceesay serves as Chairman of the Board for Life Science Cares and on the Board of Trustees at The Museum of Science in Boston. He earned his bachelor’s degree from Ithaca College and Master of Business Administration from Suffolk University’s Sawyer School of Management.